within Pharmacolibrary.Drugs.ATC.A;

model A10BD29
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.87,
    Cl             = 0.005833333333333333,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.111,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004666666666666667,
    Tlag           = 10.020000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BD29</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Sitagliptin and dapagliflozin is a fixed-dose combination antidiabetic medication used in adults for the management of type 2 diabetes mellitus. Sitagliptin is a DPP-4 inhibitor, increasing incretin levels and thus insulin secretion. Dapagliflozin is an SGLT2 inhibitor, promoting glucose excretion via the urine. The combination is approved to improve glycemic control as adjunct to diet and exercise.</p><h4>Pharmacokinetics</h4><p>No clinical pharmacokinetic studies have been published for the fixed-dose combination of sitagliptin and dapagliflozin; estimated PK parameters are based on published data for individual drugs in healthy adult volunteers after single oral dosing.</p><h4>References</h4><ol><li><p>Kazi, M, et al., &amp; Alanazi, FK (2021). Development and optimization of sitagliptin and dapagliflozin loaded oral self-nanoemulsifying formulation against type 2 diabetes mellitus. <i>Drug delivery</i> 28(1) 100–114. DOI:<a href=\"https://doi.org/10.1080/10717544.2020.1859001\">10.1080/10717544.2020.1859001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33345632/\">https://pubmed.ncbi.nlm.nih.gov/33345632</a></p></li><li><p>Kasichayanula, S, et al., &amp; Boulton, DW (2011). Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. <i>Diabetes, obesity &amp; metabolism</i> 13(1) 47–54. DOI:<a href=\"https://doi.org/10.1111/j.1463-1326.2010.01314.x\">10.1111/j.1463-1326.2010.01314.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21114603/\">https://pubmed.ncbi.nlm.nih.gov/21114603</a></p></li><li><p>Scheen, AJ (2015). Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. <i>Drugs</i> 75(1) 33–59. DOI:<a href=\"https://doi.org/10.1007/s40265-014-0337-y\">10.1007/s40265-014-0337-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25488697/\">https://pubmed.ncbi.nlm.nih.gov/25488697</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BD29;
